Ovarian cysts: presence and persistence with use of a 13.5mg levonorgestrel-releasing intrauterine system

A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents

“…In comparison, in the pivotal Phase III study, ovarian cysts were reported as an AE in 10% of participants during the first 12 months of use. However, some of these AEs may have been reported when there was an ultrasound finding of a cystic structure ≤ 3 cm if they were associated with symptoms, or if a cyst had a non-functional appearance [12].…”

A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant

“…Because reporting of ovarian cysts included women with complaints as well as those in whom cysts were detected without complaints on routine ultrasound at each study visit, the results may overstate the clinical importance of this event. Transvaginal ultrasound follow-up of 1,432 women during a 3-year phase III trial indicated that ovarian cysts associated with LNG-IUS 8 use are uncommon (18). The high spontaneous resolution rate for ovarian cysts reflects their physiologic/functional nature.…”

Molecular signatures of ovarian diseases: Insights from network medicine perspective

“…Formation of mature oocytes and production of steroid hormones that are relevant to oogenesis and folliculogenesis occur in the ovary, and dysfunctions lead to various clinical or subclinical diseases, including polycystic ovarian syndrome (PCOS), ovarian cancer, premature ovarian failure [Richards and Pangas 2010], ovarian endometriosis [Aviel-Ronen et al 2014], and ovarian cysts [Nahum et al 2015]. Ovarian cancer, which can metastasize to extra-abdominal regions, is the second most encountered gynecologic cancer worldwide [Didžiapetrienė et al 2014;Prat 2014].…”